Sirtuins transduce STACs signals through steroid hormone receptors.
Caenorhabditis elegans Proteins
/ genetics
Cell Line, Tumor
Diet
Estradiol
/ pharmacology
Estrogen Receptor alpha
/ metabolism
Estrogen Receptor beta
/ metabolism
Gonadal Steroid Hormones
/ metabolism
Humans
Isoflavones
/ pharmacology
Receptors, Cytoplasmic and Nuclear
/ genetics
Receptors, Estrogen
/ metabolism
Resveratrol
/ pharmacology
Signal Transduction
/ drug effects
Sirtuin 1
/ genetics
Sirtuins
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 03 2020
24 03 2020
Historique:
received:
27
08
2019
accepted:
06
03
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
19
12
2020
Statut:
epublish
Résumé
SIRT1 protects against several complex metabolic and ageing-related diseases (MARDs), and is therefore considered a polypill target to improve healthy ageing. Although dietary sirtuin-activating compounds (dSTACs) including resveratrol are promising drug candidates, their clinical application has been frustrated by an imprecise understanding of how their signals are transduced into increased healthspan. Recent work indicates that SIRT1 and orthologous sirtuins coactivate the oestrogen receptor/ER and the worm steroid receptor DAF-12. Here they are further shown to ligand-independently transduce dSTACs signals through these receptors. While some dSTACs elicit ER subtype-selectivity in the presence of hormone, most synergize with 17β-oestradiol and dafachronic acid respectively to increase ER and DAF-12 coactivation by the sirtuins. These data suggest that dSTACs functionally mimic gonadal steroid hormones, enabling sirtuins to transduce the cognate signals through a conserved endocrine pathway. Interestingly, resveratrol non-monotonically modulates sirtuin signalling, suggesting that it may induce hormesis, i.e. "less is more". Together, the findings suggest that dSTACs may be informational molecules that use exploitative mimicry to modulate sirtuin signalling through steroid receptors. Hence dSTACs' intrinsic oestrogenicity may underlie their proven ability to impart the health benefits of oestradiol, and also provides a mechanistic insight into how they extend healthspan or protect against MARDs.
Identifiants
pubmed: 32210296
doi: 10.1038/s41598-020-62162-0
pii: 10.1038/s41598-020-62162-0
pmc: PMC7093472
doi:
Substances chimiques
Caenorhabditis elegans Proteins
0
DAF-12 protein, C elegans
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Estrogen Receptor beta
0
Gonadal Steroid Hormones
0
Isoflavones
0
Receptors, Cytoplasmic and Nuclear
0
Receptors, Estrogen
0
Estradiol
4TI98Z838E
daidzein
6287WC5J2L
SIRT1 protein, human
EC 3.5.1.-
Sirtuin 1
EC 3.5.1.-
Sirtuins
EC 3.5.1.-
Resveratrol
Q369O8926L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5338Références
Sauve, A. A., Wolberger, C., Schramm, V. L. & Boeke, J. D. The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435–465 (2006).
doi: 10.1146/annurev.biochem.74.082803.133500
pubmed: 16756498
pmcid: 16756498
Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253–295 (2010).
doi: 10.1146/annurev.pathol.4.110807.092250
pubmed: 20078221
pmcid: 20078221
Longo, V. D. & Kennedy, B. K. Sirtuins in aging and age-related disease. Cell 126, 257–268 (2006).
doi: 10.1016/j.cell.2006.07.002
pubmed: 16873059
pmcid: 16873059
Sebastian, C., Satterstrom, K. F., Haigis, M. C. & Mostoslavsky, R. From sirtuin biology to human diseases: An update. J. Biol. Chem. 287, 42444–42452 (2012).
doi: 10.1074/jbc.R112.402768
pubmed: 23086954
pmcid: 23086954
McBurney, M. W., Clark-Knowles, K. V., Caron, A. Z. & Gray, D. A. SIRT1 is a highly networked protein that mediates the adaptation to chronic physiological stress. Genes Cancer 4, 125–134 (2013).
doi: 10.1177/1947601912474893
pubmed: 24020004
pmcid: 24020004
Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187–17195 (2005).
doi: 10.1074/jbc.M501250200
pubmed: 15749705
pmcid: 15749705
Beher, D. et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619–624 (2009).
doi: 10.1111/j.1747-0285.2009.00901.x
pubmed: 19843076
pmcid: 19843076
Sinclair, D. A. & Guarente, L. Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54, 363–380 (2014).
doi: 10.1146/annurev-pharmtox-010611-134657
pubmed: 24160699
pmcid: 24160699
Hubbard, B. P. et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219 (2013).
doi: 10.1126/science.1231097
pubmed: 23471411
pmcid: 23471411
Dai, H. et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat. Commun. 6, 7645 (2015).
doi: 10.1038/ncomms8645
pubmed: 26134520
pmcid: 4506539
Cao, D. et al. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev. 29, 1316–1325 (2015).
doi: 10.1101/gad.265462.115
pubmed: 26109052
pmcid: 4495401
Price, N. L. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 675–690 (2012).
doi: 10.1016/j.cmet.2012.04.003
pubmed: 22560220
pmcid: 3545644
Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421–433 (2012).
doi: 10.1016/j.cell.2012.01.017
pubmed: 22304913
pmcid: 3431801
Hubbard, B. P. & Sinclair, D. A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146–154 (2014).
doi: 10.1016/j.tips.2013.12.004
pubmed: 24439680
pmcid: 3970218
Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225–238 (2012).
doi: 10.1038/nrm3293
pubmed: 22395773
pmcid: 4872805
Lavu, S., Boss, O., Elliott, P. J. & Lambert, P. D. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7, 841–853 (2008).
doi: 10.1038/nrd2665
pubmed: 18827827
Dixon, R. A. Phytoestrogens. Annu. Rev. Plant Biol. 55, 225–261 (2004).
doi: 10.1146/annurev.arplant.55.031903.141729
Morito, K. et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol. Pharm. Bull. 24, 351–356 (2001).
doi: 10.1248/bpb.24.351
pubmed: 11305594
pmcid: 11305594
Kuiper, G. G. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863–870 (1997).
doi: 10.1210/endo.138.3.4979
pubmed: 9048584
pmcid: 9048584
An, J. P., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N. & Leitman, D. C. Estrogen receptor β–selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276, 17808–17814 (2001).
doi: 10.1074/jbc.M100953200
pubmed: 11279159
Mueller, S. O., Simon, S., Chae, K., Metzler, M. & Korach, K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol. Sci. 80, 14–25 (2004).
doi: 10.1093/toxsci/kfh147
pubmed: 15084758
Gehm, B. D., McAndrews, J. M., Chien, P. Y. & Jameson, J. L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94, 14138–14143 (1997).
doi: 10.1073/pnas.94.25.14138
pubmed: 9391166
Bayele, H. K. A conserved mechanism of sirtuin signalling through steroid hormone receptors. Biosci. Rep. 39, BSR20193535 (2019).
doi: 10.1042/BSR20193535
pubmed: 31746335
pmcid: 6904774
Antebi, A., Yeh, W. H., Tait, D., Hedgecock, E. M. & Riddle, D. L. daf-12 encodes a nuclear receptor that regulates the dauer diapause and developmental age in C. elegans. Genes Dev. 14, 1512–1527 (2000).
pubmed: 316684
pmcid: 316684
Motola, D. L. et al. Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. Cell 124, 1209–1223 (2006).
doi: 10.1016/j.cell.2006.01.037
pubmed: 16529801
Yamawaki, T. M. et al. The somatic reproductive tissues of C. elegans promote longevity through steroid hormone signaling. PLoS Biol. 8, e1000468 (2010).
doi: 10.1371/journal.pbio.1000468
pubmed: 20824162
pmcid: 2930862
Bemd, V. D., Kuiper, G. J., Pols, G. G., Van Leeuwen, H. A. & Distinct, J. P. effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem. Biophys. Res. Commun. 261, 1–5 (1999).
doi: 10.1006/bbrc.1999.0864
Pace, P., Taylor, J., Suntharalingam, S., Coombes, R. C. & Ali, S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J. Biol. Chem. 272, 25832–25838 (1997).
doi: 10.1074/jbc.272.41.25832
pubmed: 9325313
Paech, K. et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277, 1508–1510 (1997).
doi: 10.1126/science.277.5331.1508
pubmed: 9278514
Wittmann, B. M., Sherk, A. & McDonnell, D. P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67, 9549–9560 (2007).
doi: 10.1158/0008-5472.CAN-07-1590
pubmed: 17909066
pmcid: 17909066
Boonmuen, N. et al. Licorice root components in dietary supplements are selective estrogen receptor modulators with a spectrum of estrogenic and anti-estrogenic activities. Steroids 105, 42–49 (2016).
doi: 10.1016/j.steroids.2015.11.006
pubmed: 26631549
pmcid: 26631549
Kim, M. Y., Woo, E. M., Chong, Y. T., Homenko, D. R. & Kraus, W. L. Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the DNA binding and transactivation activities of the receptor. Mol. Endocrinol. 20, 1479–1493 (2006).
doi: 10.1210/me.2005-0531
pubmed: 16497729
pmcid: 16497729
Li, S. et al. Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway. Sci. Rep. 5, 16815 (2015).
doi: 10.1038/srep16815
pubmed: 26568398
pmcid: 26568398
Suriyani, Y. In silico analysis of formononetin compound as a breast anticancer. Revista Latinoamericana de Hipertensión 13, 579–583 (2018).
Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196 (2003).
doi: 10.1038/nature01960
Wood, J. G. et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686–689 (2004).
doi: 10.1038/nature02789
pubmed: 15254550
pmcid: 15254550
Valenzano, D. R. et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Current Biol. 16, 296–300 (2006).
doi: 10.1016/j.cub.2005.12.038
Srinivasan, S. et al. Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat. Chem. Biol. 9, 326–332 (2013).
doi: 10.1038/nchembio.1214
pubmed: 23524984
pmcid: 23524984
Nwachukwu, J. C. et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife. 3, e02057 (2014).
doi: 10.7554/eLife.02057
pubmed: 4017646
pmcid: 4017646
Li, L., Andersen, M. E., Heber, S. & Zhang, Q. Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J. Mol. Endocrinol. 38, 569–585 (2007).
doi: 10.1677/JME-07-0003
pubmed: 17496158
pmcid: 17496158
Calabrese, E. J. & Baldwin, L. A. Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol. Sci. 22, 285–291 (2001).
doi: 10.1016/S0165-6147(00)01719-3
pubmed: 11395156
pmcid: 11395156
Xu, H. et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 4, 447–451 (1998).
doi: 10.1038/nm0498-447
pubmed: 9546791
pmcid: 9546791
Arevalo, M. A., Azcoitia, I. & Garcia-Segura, L. M. The neuroprotective actions of oestradiol and oestrogen receptors. Nat. Rev. Neurosci. 16, 17–29 (2015).
doi: 10.1038/nrn3856
pubmed: 25423896
pmcid: 25423896
Morselli, E. et al. The effects of oestrogens and their receptors on cardiometabolic health. Nat. Rev. Endocrinol. 13, 352–364 (2017).
doi: 10.1038/nrendo.2017.12
pubmed: 28304393
pmcid: 28304393
Deroo, B. J. & Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 116, 561–570 (2006).
doi: 10.1172/JCI27987
pubmed: 16511588
pmcid: 16511588
Mauvais-Jarvis, F., Clegg, D. J. & Hevener, A. L. The role of estrogens in control of energy balance and glucose homeostasis. Endocr. Rev. 34, 309–338 (2013).
doi: 10.1210/er.2012-1055
pubmed: 23460719
pmcid: 23460719
Jia, M., Dahlman-Wright, K. & Gustafsson, J. Å. Estrogen receptor alpha and beta in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 29, 557–568 (2015).
doi: 10.1016/j.beem.2015.04.008
pubmed: 26303083
pmcid: 26303083
Liu, F. et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat. Neurosci. 11, 334–343 (2008).
doi: 10.1038/nn2057
pubmed: 18297067
pmcid: 18297067
Cui, J., Shen, Y. & Li, R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol. Med. 19, 197–209 (2013).
doi: 10.1016/j.molmed.2012.12.007
pubmed: 23348042
pmcid: 23348042
Morito, K. et al. Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol. Pharm. Bull. 25, 48–52 (2002).
doi: 10.1248/bpb.25.48
pubmed: 11824555
pmcid: 11824555
Warnsmann, V., Hainbuch, S. & Osiewacz, H. D. Quercetin-induced lifespan extension in Podospora anserina requires methylation of the flavonoid by the O-methyltransferase PaMTH1. Front. Genet. 9, 160 (2018).
doi: 10.3389/fgene.2018.00160
pubmed: 29780405
pmcid: 29780405
Abd El-Mohsen, M. et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 96, 62–70 (2006).
doi: 10.1079/BJN20061810
pubmed: 16869992
pmcid: 16869992
Jackson, R. L., Greiwe, J. S. & Schwen, R. J. Emerging evidence of the health benefits of S-equol, an estrogen receptor b agonist. Nutr. Rev. 69, 432–448 (2011).
doi: 10.1111/j.1753-4887.2011.00400.x
pubmed: 21790611
pmcid: 21790611
Bode, L. M. et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 97, 295–309 (2013).
doi: 10.3945/ajcn.112.049379
pubmed: 23283496
pmcid: 23283496
Pallauf, K. et al. Resveratrol, lunularin and dihydroresveratrol do not act as caloric restriction mimetics when administered intraperitoneally in mice. Sci. Rep. 9, 4445 (2019).
doi: 10.1038/s41598-019-41050-2
pubmed: 30872769
pmcid: 30872769
Howitz, K. T. & Sinclair, D. A. Xenohormesis: sensing the chemical cues of other species. Cell 133, 387–391 (2008).
doi: 10.1016/j.cell.2008.04.019
pubmed: 18455976
pmcid: 18455976
Weiskirchen, S. & Weiskirchen, R. Resveratrol: how much wine do you have to drink to stay healthy? Adv. Nutr. 7, 706–18 (2016).
doi: 10.3945/an.115.011627
pubmed: 27422505
pmcid: 27422505
Mattson, M. P. Hormesis and disease resistance: activation of cellular stress response pathways. Hum. Exp. Toxicol. 27, 155–162 (2008).
doi: 10.1177/0960327107083417
pubmed: 18480142
pmcid: 18480142
Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C. & Klinge, C. M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinol. 141, 3657–3667 (2000).
doi: 10.1210/endo.141.10.7721
Bhat, K. P. et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61, 7456–7463 (2001).
pubmed: 11606380
pmcid: 11606380
Pearson, K. J. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8, 157–168 (2008).
doi: 10.1016/j.cmet.2008.06.011
pubmed: 18599363
pmcid: 18599363
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y. & Holz, M. K. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 1, 35 (2017).
doi: 10.1038/s41698-017-0038-6
pubmed: 28989978
pmcid: 28989978
Barger, J. L. et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3, e2264 (2008).
doi: 10.1371/journal.pone.0002264
pubmed: 18523577
pmcid: 18523577
Brasnyó, P. et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106, 383–938 (2011).
doi: 10.1017/S0007114511000316
pubmed: 21385509
pmcid: 21385509
Cho, S. J., Jung, U. J. & Choi, M. S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Brit. J. Nutr. 108, 2166–2175 (2012).
doi: 10.1017/S0007114512000347
pubmed: 22414733
pmcid: 22414733
Zarse, K. et al. Differential effects of resveratrol and SRT1720 on lifespan of adult Caenorhabditis elegans. Horm. Metab. Res. 42, 837–839 (2010).
doi: 10.1055/s-0030-1265225
pubmed: 20925017
pmcid: 20925017
Aquilano, K. et al. Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J. Biol. Chem. 285, 21590–21599 (2010).
doi: 10.1074/jbc.M109.070169
pubmed: 20448046
pmcid: 20448046
Chen, J. Q., Eshete, M., Alworth, W. L. & Yager, J. D. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J. Cell. Biochem. 93, 358–373 (2004b).
doi: 10.1002/jcb.20178
pubmed: 15368362
pmcid: 15368362
Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122 (2006).
doi: 10.1016/j.cell.2006.11.013
pubmed: 17112576
pmcid: 17112576
Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342 (2006).
doi: 10.1038/nature05354
pubmed: 17086191
pmcid: 17086191
Lee, J., Kwon, G., Park, J., Kim, J. K. & Lim, Y. H. Brief Communication: SIR-2.1-dependent lifespan extension of Caenorhabditis elegans by oxyresveratrol and resveratrol. Exp. Biol. Med. 241, 1757–1763 (2016).
doi: 10.1177/1535370216650054
Boily, G., He, X. H., Pearce, B., Jardine, K. & McBurney, M. W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28, 2882–2893 (2009).
doi: 10.1038/onc.2009.147
pubmed: 19503100
pmcid: 19503100
Klinge, C. M. et al. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem. 280, 7460–7468 (2005).
doi: 10.1074/jbc.M411565200
pubmed: 15615701
pmcid: 15615701
Lu, R. & Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 179, 297–304 (1999).
doi: 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P
pubmed: 10228948
pmcid: 10228948
Chen, Y., Tseng, S. H., Lai, H. S. & Chen, W. J. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136, 57–66 (2004).
doi: 10.1016/j.surg.2004.01.017
pubmed: 15232540
pmcid: 15232540
Harper, C. E. et al. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28, 1946–1953 (2007).
doi: 10.1093/carcin/bgm144
pubmed: 17675339
pmcid: 17675339
Catalgol, B., Batirel, S., Taga, Y. & Ozer, N. K. Resveratrol: French paradox revisited. Front. Pharmacol. 3, 141 (2012).
doi: 10.3389/fphar.2012.00141
pubmed: 22822401
pmcid: 22822401
Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997).
doi: 10.1038/39645
pubmed: 9338790
pmcid: 9338790
Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998).
doi: 10.1016/S0092-8674(00)81717-1
pubmed: 9875847
pmcid: 9875847
Förster, C. et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99, 15578–15583 (2002).
doi: 10.1073/pnas.192561299
pubmed: 12438700
pmcid: 12438700
Imamov, O. et al. Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA 101, 9375–9380 (2004).
doi: 10.1073/pnas.0403041101
pubmed: 15187231
pmcid: 15187231
Foley, E. F., Jazaeri, A. A., Shupnik, M. A., Jazaeri, O. & Rice, L. W. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 60, 245–248 (2000).
pubmed: 10667568
pmcid: 10667568
Wang, L., Andersson, S., Warner, M. & Gustafsson, J. A. Estrogen receptor (ER)beta knockout mice reveal a role for ERbeta in migration of cortical neurons in the developing brain. Proc. Natl Acad. Sci. USA 100, 703–708 (2003).
doi: 10.1073/pnas.242735799
pubmed: 12515851
pmcid: 12515851
McPherson, S. J. et al. Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinol. 148, 566–574 (2007).
doi: 10.1210/en.2006-0906
Paruthiyil, S. et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64, 423–428 (2004).
doi: 10.1158/0008-5472.CAN-03-2446
pubmed: 14729654
pmcid: 14729654
Gong, P. et al. Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens. Nucl. Recept. Signal. 12, e001 (2014).
doi: 10.1621/nrs.12001
pubmed: 25363786
pmcid: 25363786
Lagari, V. S. & Levis, S. Phytoestrogens for menopausal bone loss and climacteric symptoms. J. Steroid Biochem. Mol. Biol. 139, 294–301 (2014).
doi: 10.1016/j.jsbmb.2012.12.002
pubmed: 23246986
pmcid: 23246986
Dueregger, A. et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 6, 4491–4519 (2014).
doi: 10.3390/nu6104491
pubmed: 25338271
pmcid: 25338271
Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179 (2007).
doi: 10.1038/sj.emboj.7601758
pubmed: 17581637
pmcid: 17581637
Eick, G. N. & Thornton, J. W. Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol. Cell. Endocrinol. 334, 31–38 (2011).
doi: 10.1016/j.mce.2010.09.003
pubmed: 20837101
Markov, G. V. et al. Origin of an ancient hormone/receptor couple revealed by resurrection of an ancestral estrogen. Sci. Adv. 3, e1601778 (2017).
doi: 10.1126/sciadv.1601778
pubmed: 28435861
pmcid: 5375646
Oberdörster, E. et al. Common phytochemicals are ecdysteroid agonists and antagonists: a possible evolutionary link between vertebrate and invertebrate steroid hormones. J. Steroid Biochem. Mol. Biol. 77, 229–238 (2001).
doi: 10.1016/S0960-0760(01)00067-X
pubmed: 11457661
Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93–105 (2002).
doi: 10.1016/S0092-8674(02)00817-6
pubmed: 12151000
Takeuchi, S. et al. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol. Pharm. Bull. 32, 195–202 (2009).
doi: 10.1248/bpb.32.195
pubmed: 19182375
Nilsson, S., Koehler, K. F. & Gustafsson, J. Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 10, 778–92 (2011).
doi: 10.1038/nrd3551
pubmed: 21921919
Paterni, I., Granchi, C., Katzenellenbogen, J. A. & Minutolo, F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids 90, 13–29 (2014).
doi: 10.1016/j.steroids.2014.06.012
pubmed: 24971815
Melis, G. B. et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J. Endocrinol. Invest. 15, 755–761 (1992).
doi: 10.1007/BF03347647
pubmed: 1491124
Gennari, C. et al. Effect of ipriflavone – a synthetic derivative of natural isoflavones – on bone mass loss in the early years after menopause. Menopause 61(Suppl 1), 9–15 (1998).
Snyder, S. A., Gollner, A. & Chiriac, M. I. Regioselective reactions for programmable resveratrol oligomer synthesis. Nature 474, 461–466 (2011).
doi: 10.1038/nature10197
pubmed: 21697944
pmcid: 3179663
Lappano, R. et al. Structure–activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res. 53, 845–858 (2009).
doi: 10.1002/mnfr.200800331
pubmed: 19496085
Gao, Y. & He, C. Anti-proliferative and anti-metastasis effects of ten oligostilbenes from the seeds of Paeonia suffruticosa on human cancer cells. Oncol. Lett. 13, 4371–4377 (2017).
Xue, Y. Q. et al. Resveratrol oligomers for the prevention and treatment of cancers. Oxid. Med. Cell Longev. 2014, 765832 (2014).
doi: 10.1155/2014/765832
pubmed: 24799982
pmcid: 3988857
Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today 15, 757–765 (2010).
doi: 10.1016/j.drudis.2010.07.005
pubmed: 20692359
Fischer, N. et al. The resveratrol derivatives trans-3,5-dimethoxy-4-fluoro-4′-hydroxystilbene and trans-2,4′,5-trihydroxystilbene decrease oxidative stress and prolong lifespan in Caenorhabditis elegans. J. Pharm. Pharmacol. 69, 73–81 (2017).
doi: 10.1111/jphp.12657
pubmed: 27882602